Clinical trials using JAKi in Graft-versus-Host-Disease according to... | Download Scientific Diagram
Incyte's Graft-Versus-Host Trial Fails to Meet Primary Endpoint | BioSpace
Predicting Complete Response to Itacitinib and Corticosteroids in Acute Graft Versus Host Disease - Biology of Blood and Marrow Transplantation
Clinical trials using JAKi in Graft-versus-Host-Disease according to... | Download Scientific Diagram
Clinical Trials of Itacitinib for Chronic and Acute GVHD
Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases - ScienceDirect
Frontiers | New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions | Immunology
Ongoing clinical trials of PD-1/PD-L1 immunotherapeutics in breast cancer | Download Table
Itacitinib prevents xenogeneic GVHD in humanized mice | Bone Marrow Transplantation
Itacitinib (INCB039110) | JAK1 Inhibitor | MedChemExpress
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies - Clinical Lymphoma, Myeloma and Leukemia
The Lancet Haematology on Twitter: "Zeiser also discussed GRAVITAS-301: addition of itacitinib, a JAK1 inhibitor, did not improve response compared with standard first line therapy for acute #GVHD. Corticosteroids remain the standard
Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases - ScienceDirect
Impact of itacitinib on xGVHD Survival (a), GVHD scoring (b) and weight... | Download Scientific Diagram
Itacitinib | C26H23F4N9O - PubChem
A Phase 2, Double-Blind, Dose-Ranging, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis | Clinical Research Trial Listing ( Ulcerative Colitis ) (
![PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/265b8d3517575964e518b92944c9558171cdf15d/6-Table1-1.png "PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar")
PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar
PDF) The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib
Itacitinib adipate | C32H33F4N9O5 - PubChem
Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease | Business Wire
![PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/265b8d3517575964e518b92944c9558171cdf15d/8-Table2-1.png "PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar")
PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar
Itacitinib Clinical Trials for Chronic and Acute GVHD
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study | Journal for ImmunoTherapy of Cancer
Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associa
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial - The Lancet Haematology
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease - ScienceDirect
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial - The Lancet Haematology
![PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/265b8d3517575964e518b92944c9558171cdf15d/10-Figure1-1.png "PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar")
PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma - ScienceDirect
